6:25 PM
 | 
Nov 15, 2013
 |  BC Extra  |  Company News

IQWiG rebuffs Roche's Erivedge

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that Erivedge vismodegib from Roche (SIX:ROG; OTCQX:RHHBY) has "no additional benefit" to treat symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC in...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >